Silexion Therapeutics Corp — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center (July 29, 2026) following regulatory approvals from Israel and Germany. The company closed a public offering on August 13, 2026, yielding $2.5M gross proceeds ($2.1M net). New preclinical data demonstrated immune-sensitization across three pathways and four KRAS mutations, supporting future combination with anti-PD-(L)1 therapies. Q2 2026 net loss was $3.6M (vs. $2.5M year-over-year); cash fell from $6.0M (Dec 31, 2025) to $2.2M (June 30, 2026). The company claims restoration of Nasdaq compliance with ~$3.2M shareholders' equity, exceeding the $2.5M minimum.
Why this rating
Clinical initiation and $2.5M capital raise are material for $4.6M-asset company. Trial start is pivotal milestone; cash runway remains tight despite financing.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.